Literature DB >> 17905201

Interferon-beta is neuroprotective against the toxicity induced by activated microglia.

Shijie Jin1, Jun Kawanokuchi, Tetsuya Mizuno, Jinyan Wang, Yoshifumi Sonobe, Hideyuki Takeuchi, Akio Suzumura.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system characterized by demyelination, T lymphocyte infiltration, and neuronal degeneration. Interferon-beta (IFN)-beta reduces symptoms of the relapsing-remitting form of MS. In this study, we investigated whether IFN-beta is neuroprotective against the toxicity induced by activated microglia in cortical neurons and microglia co-cultures. IFN-beta suppressed the production of glutamate and superoxide by activated microglia to 70% and 75% of lipopolysaccharide stimulation, respectively, and prevented microglial-induced neuronal cell death. Although IFN-beta enhanced the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and nitric oxide (NO) by activated microglia, these molecules did not directly induce neurotoxicity in cultured cortical neurons. IFN-beta did not prevent neuronal cell death induced by the peroxynitrite donor 3-morpholinosydnonimine (SIN-1) or ionotropic glutamate receptor agonists such as N-methyl-D-aspartic acid (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). These results suggest that IFN-beta may be a useful agent counteracting neurotoxicity associated with activated microglia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905201     DOI: 10.1016/j.brainres.2007.08.055

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

Review 1.  Toll-like receptor signaling in endogenous neuroprotection and stroke.

Authors:  B J Marsh; R L Williams-Karnesky; M P Stenzel-Poore
Journal:  Neuroscience       Date:  2008-08-12       Impact factor: 3.590

Review 2.  Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis.

Authors:  Debora Giunti; Benedetta Parodi; Christian Cordano; Antonio Uccelli; Nicole Kerlero de Rosbo
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

Review 3.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

4.  Interferon-α induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor.

Authors:  Cari F Kessing; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-12-17       Impact factor: 2.607

Review 5.  Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

6.  It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection.

Authors:  Philberta Y Leung; Amy Eb Packard; Mary P Stenzel-Poore
Journal:  Future Neurol       Date:  2009

7.  Correction to: Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  Intrinsic innate immunity fails to control herpes simplex virus and vesicular stomatitis virus replication in sensory neurons and fibroblasts.

Authors:  Pamela C Rosato; David A Leib
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

9.  Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia.

Authors:  Brenda J Marsh; Susan L Stevens; Brian Hunter; Mary P Stenzel-Poore
Journal:  Stroke       Date:  2008-12-08       Impact factor: 7.914

10.  Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents.

Authors:  Núria Gresa-Arribas; Cristina Viéitez; Guido Dentesano; Joan Serratosa; Josep Saura; Carme Solà
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.